The researchers concluded that patients with circulating tumour cells with more N - terminals than C - terminals had
the androgen receptor variants.
Not exact matches
The AR - V7
variant is formed when an
androgen receptor loses the end part of the
receptor, called the C - terminal end; this is deleted due to an error in RNA processing in tumour cells, leaving only the beginning part of the
receptor, the N - terminal end.
«Recent data have shown that a
variant of the
androgen receptor called AR - V7, found in tumour cells circulating in the blood of patients with metastatic CRPC, predicted resistance to treatment with enzalutamide and abiraterone,» she will say.
Researchers believed that galeterone could be effective against CRPC because it disrupts the
androgen receptor signalling pathways that are involved in the cancer, and preclinical work has shown it is active against the AR - V7
variant.